Fallopian Tube Cancer Market - Size, Share, Outlook, and Forecast till 2026

Fallopian Tubes also called as uterine tube are pair of tubes, which carry an egg from the ovary to the uterus. Fallopian tube cancer also called as tubal cancer is caused due to uncontrolled growth of cells in fallopian tubes that connect the ovaries and the uterus. This is very rare type of cancer and it is characterized by symptoms such as abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish, and pelvic mass at the time of diagnosis. Although fallopian tube cancer can occur at any age, it majorly affects women between the ages of 50 and 60, age. Also, it is more common in Caucasian women who had few or no children.

Increasing prevalence of gynecological and reproductive disorders such as breast cancer, endometrial cancer, cervical cancer, ovarian cancer, and vaginal cancer is key factor fueling growth of the fallopian tube cancer market. Previous research studies reported that women who have inherited the gene linked to breast and ovarian cancer, called BRCA1, are show an increased risk of developing fallopian tube cancer. According to the article published in the University of California San Francisco, fallopian tube cancer is rare and accounts for 2 percent of all gynecologic cancers. Around 1,500 to 2,000 cases of fallopian tube cancer have been reported worldwide. An estimated 300 to 400 women are diagnosed with the condition annually in the U.S.

Key Developments in Fallopian Tube Cancer Market

Market players are engaged in developing novel drugs for treatment of fallopian tube cancer in order to meet increasing demand from healthcare sector, which in turn is driving growth of the fallopian tube cancer market size. Furthermore, launch and novel drugs to treat the fallopian cancer and their approval by regulatory bodies is boosting growth of the fallopian tube cancer market. For instance, in June 2018, the Genentech, biotechnology company received Food and Drug Administration (FDA) approval for combination of Avastin (bevacizumab) plus the chemotherapy agents carboplatin and paclitaxel, followed by Avastin alone, for the treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. Key players operating in fallopian tube cancer market include AbbVie Inc, Amgen Inc, Arrien Pharmaceuticals LLC, AstraZeneca Plc., Atara Biotherapeutics Inc, Bayer AG, BeiGene Ltd, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, Caladrius Biosciences Inc, Celgene Corp, Celldex Therapeutics Inc, Dr. Reddy’s Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Co, EpiThany Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd among others.

Global Cancer Screening Market (2018-2023)

Published Date : Sep 2018

Global cancer screening market The cancer screening market is witnessing a rapid upsurge due to a rapid rise in the number of cancer cases. There lies an immediate need to seek early diagnosis and precautionary measures. The growth of the market lies in the adoption of innovative screen...

North America Cancer Screening Market (2018-2023)

Published Date : Sep 2018

North America cancer screening market North America is leading the cancer screening market. The region is technologically equipped and being a developed economy it is efficiently catering to the rising incidence of cancer cases. The market is forecasted to grow at a compound annual gr...

MEA Cancer Screening Market (2018-2023)

Published Date : Sep 2018

Middle East and Africa cancer screening market The Middle East and Africa (MEA) cancer screening market is growing at a very slow rate. The MEA market is projected to reach USD 50.61 Bn by 2023, at a compound annual growth rate (CAGR) of 11.5% during the forecast period (2018-2023).Th...

Latin America Cancer Screening Market (2018-2023)

Published Date : Sep 2018

Latin America cancer screening market The Latin America cancer screening market is currently valued at USD 21.24 billion and is forecasted to achieve a growth rate of 7.19 % compound annual growth rate (CAGR) leading to a regional revenue of USD 30.06 Bn. Latin America's growth is muc...

Europe Cancer Screening Market (2018-2023)

Published Date : Sep 2018

Europe cancer screening market Europe after North America is the second largest market leading the cancer screening market. The market is forecasted to grow at a compound annual growth rate of (CAGR) of 8.1% resulting in an annual revenue of USD 22.43 Bn during the forecast period (20...

Cancer Screening Market in the U.S.A. (2018-2023)

Published Date : Sep 2018

Cancer screening market in the U.S.A. The United States Of America (U.S.A.) is leading the cancer screening market. The rising incidence of cancer along with growing awareness regarding prevention of diseases and diagnosis is a key driver for the market. There is increased technological...

Cancer Screening Market in the U.K. (2018-2023)

Published Date : Sep 2018

Cancer screening market in the U.K. The United Kingdom (U.K.) stands next to the United States of America (U.S.A.) in coming up with latest technologies to combat the spread of cancer. The cancer screening market in the U.K. is expected to reach USD Bn by 2023 at a CAGR of 8.5%. C...

Cancer Screening Market in India (2018-2023)

Published Date : Sep 2018

Cancer screening market in India The Asia-Pacific is a growing region and holds lots of positive socio-economic factors suitable for the growth and progress of the market primarily because of its association with the global value chains (GVCs). India being a part of the Asia-Pacific re...

Cancer Screening Market in China (2018-2023)

Published Date : Sep 2018

Cancer screening market in China China's demand for cancer screening has grown at a fast pace in the past decade. Cancer is one of the most significant healthcare burdens in China. The Chinese economy maintains a high pace of growth stimulated by the consecutive increase in capital inve...

Asia Pacific Cancer Screening Market (2018-2023)

Published Date : Sep 2018

Asia-Pacific cancer screening market Asia-Pacific is a rapidly growing cancer market. The market is forecasted to grow at a compound annual growth rate (CAGR) of 17.3% resulting in annual revenue of USD 32.26 Bn during the forecast period (2018-2023). Asia Pacific is rapidly adopting ...

 

Select License :

  • Single User : $4500
  • Multiple User : $7000
  • Corporate User : $10000

Happy To Assist You

Assist you at Worldwide Market Reports

We will be happy to help you find what you need. Please call us or write to us:

Worldwide Market Reports Benefits

Custom Research Solution

Talk to our research consultant to design an exclusive report as per your research needs.

Customer Fulfilment

We aim to fulfil client's research demands with tailored research solutions.

Quick Turnaround Time Reports

We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

360-degree Approach

We cover each industry from supply and demand side with an aim to provide a most holistic research study.